Fulcrum Therapeutics, Inc.
3.84USD
+0.0200 (+0.52%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 6.3M | 2.8M | 80.0M | 0.0 | 0.0 | 0.0 |
| Q1 | 2.6M | 295.0K | 0.0 | — | — | — |
| Q2 | 1.9M | 880.0K | 80.0M | 0.0 | — | — |
| Q3 | 1.2M | 759.0K | 0.0 | 0.0 | 0.0 | — |
| Q4 | 685.0K* | 871.0K* | 0.0* | 0.0* | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.002 | -.001 | -.000 | -.001 | -.657 | -.488 |
| Q1 | -.001 | -.000 | -.357 | -.229 | -.250 | — |
| Q2 | -.001 | -.318 | .741 | -.230 | -.340 | — |
| Q3 | -.000 | -.327 | -.293 | -.254 | -.111 | — |
| Q4 | -.482* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.335* |
| -.222* |
| -.267* |
| -.064 |
| — |